Pathophysiology of atypical hemolytic uremic syndrome: Ten years of progress, from the laboratory to patient;Physiopathologie du Syndrome Hémolytique et Urémique atypique - Dix ans de progrés, du laboratoire au patient

Biologie Aujourd'hui

Volumn 207, Issue 4, 2013, Pages 231-240

  Frémeaux Bacchi, Véronique ^a,b  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Complement; DGKe; Endothelial cells; Hemolytic Uremic Syndrome

Indexed keywords

COMPLEMENT;

ADULT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLASSIFICATION; COMPLEMENT ACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; MULTIFACTORIAL INHERITANCE; TRENDS;

ADULT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOMEDICAL RESEARCH; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; MULTIFACTORIAL INHERITANCE;

EID: 84901019327     PISSN: 21050678     EISSN: 21050686     Source Type: Journal    
DOI: 10.1051/jbio/2013027     Document Type: Article

References (36)

1. Bienaimé F., Dragon-Durey M.A., Régnier C.H., Nilsson S.C., Kwan W.H., Blouin J., Jablonski M., Renault N., Rameix-Welti M.A., Loirat C., Sautes-Fridman C., Villoutreix B.O., Blom A.M., Frémeaux-Bacchi V., Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int, 2010, 77, 339-349.
2. Blanc C., Roumenina L.T., Ashraf Y., Hyvarinen S., Sethi S.K., Ranchin B., Niaudet P., Loirat C., Gulati A., Bagga A., Fridman W.H., Sautes-Fridman C., Jokiranta T.S., Frémeaux-Bacchi V., Dragon-Durey M.A., Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol, 2012, 189, 3528-3537.
3. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Frémeaux-Bacchi V., Rodriguez de Cordoba S., Pinto S., Goodship T.H., Alberti M., Ribes D., Valoti E., Remuzzi G., Noris M., Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol, 2013, 24, 475-486.
4. Cornec-Le Gall E., Delmas Y., de Parscau L., Doucet L., Ogier H., Benoist J.F., Frémeaux-Bacchi V., Le Meur Y., Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency. Am J Kidney Dis, 2014, 63, 119-123.
5. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M., Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361, 345-357.
6. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., Frémeaux-Bacchi V., Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol, 2005, 16, 555-563.
7. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J.B., Kabir M.G., Backx P.H., Gerber H.P., Ferrara N., Barisoni L., Alpers C.E., Quaggin S.E., VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 2008, 358, 1129-1136.
8. Ermini L., Goodship T.H., Strain L., Weale M.E., Sacks S.H., Cordell H.J., Frémeaux-Bacchi V., Sheerin N.S., Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol, 2011, 49, 640-648.
9. Frémeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman W.H., Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet, 2004, 41, e84.
10. Frémeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet, Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R., Hauhart R., Meunier V.H., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H., Atkinson J.P., Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood, 2008, 112, 4948-4952.
11. Frémeaux-Bacchi V., Fakhouri F., Garnier A., Bienaimé F., Dragon-Durey M.A., Ngo S., Moulin B., Servais A., Provot F., Rostaing L., Burtey S., Niaudet P., Deschênes G., Lebranchu Y., Zuber J., C. Loirat., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol, 2013, 8, 554-562.
12. Frimat M., Tabarin F., Dimitrov J.D., Poitou C., Halbwachs-Mecarelli L., Frémeaux-Bacchi V., Roumenina L.T., Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292.
13. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., Lopez-Trascasa M., Sanchez-Corral P., Morgan B.P., Rodriguez de Cordoba S., Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2007, 104, 240-245.
14. Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., Chatelet V., Mousson C., Mourad G., Bridoux F., Cassuto E., Loirat C., Rondeau E., Delahousse M., Frémeaux-Bacchi V., Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant, 2013, 13, 663-675.
15. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med, 2013, 368, 2169-2181.
16. Lemaire M., Frémeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W., Overton J.D., Mane S.M., Nurnberg G., Altmuller J., Thiele H., Morin D., Deschênes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E., Nurnberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J., Loirat C., Lifton R.P., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet, 2013, 45, 531-536.
17. Loirat C., Frémeaux-Bacchi V., Atypical hemolytic uremic syndrome. Orphanet J Rare Dis, 2012, 6, 60.
18. Menne J., Nitschke M., Stingele R., Abu-Tair M., Beneke J., Bramstedt J., Bremer J.P., Brunkhorst R., Busch V., Dengler R., Deuschl G., Fellermann K., Fickenscher H., Gerigk C., Goettsche A., Greeve J., Hafer C., Hagenmuller F., Haller H., Herget-Rosenthal S., Hertenstein B., Hofmann C., Lang M., Kielstein J.T., Klostermeier U.C., Knobloch J., Kuehbacher M., Kunzendorf U., Lehnert H., Manns M.P., Menne T.F., Meyer T.N., Michael C., Munte T., Neumann-Grutzeck C., Nuernberger, Pavenstaedt H., Ramazan L., Renders L., Repenthin J., Ries W., Rohr A., Rump L.C., Samuelsson O., Sayk F., Schmidt B.M., Schnatter S., Schocklmann H., Schreiber S., von Seydewitz C.U., Steinhoff J., Stracke S., Suerbaum S., van de Loo A., Vischedyk M., Weissenborn K., Wellhoner P., Wiesner M., Zeissig S., Buning J., Schiffer M., Kuehbacher T., Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ, 2012, 345, e4565.
19. Morigi M., Galbusera M., Gastoldi S., Locatelli M., Buelli S., Pezzotta A., Pagani C., Noris M., Gobbi M., Stravalaci M., Rottoli D., Tedesco F., Remuzzi G., Zoja C., Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol, 2011, 187, 172-180.
20. Noris M., Remuzzi G., Atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361, 1676-1687.
21. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., Gamba S., Remuzzi G., Familial haemolytic uraemic syndrome and an MCP mutation. Lancet, 2003, 362, 1542-1547.
22. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010, 5, 1844-1859.
23. Ozaltin F., Li B., Rauhauser A., An S.W., Soylemezoglu O., Gonul I.I., Taskiran E.Z., Ibsirlioglu T., Korkmaz E., Bilginer Y., Duzova A., Ozen S., Topaloglu R., Besbas N., Ashraf S., Du Y., Liang C., Chen P., Lu D., Vadnagara K., Arbuckle S., Lewis D., Wakeland B., Quigg R.J., Ransom R.F., Wakeland E.K., Topham M.K., Bazan N.G., Mohan C., Hildebrandt F., Bakkaloglu A., Huang C.L., Attanasio M., DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol, 2013, 24, 377-384.
24. Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J., Botto M., Uncontrolled C3 activation causes membrano-proliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet, 2002, 31, 424-428.
25. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., Moss J., Walport M.J., Cook H.T., de Cordoba S.R., Botto M., Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med, 2007, 204, 1249-1256.
26. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H., Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2003, 100, 12966-12971.
27. Roumenina L.T., Loirat C., Dragon-Durey M.A., Halbwachs-Mecarelli L., Sautes-Fridman C., Frémeaux-Bacchi V., Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods, 2011, 365, 8-26.
28. Roumenina L.T., Frimat M., Miller E.C., Provot F., Dragon-Durey M.A., Bordereau P., Bigot S., Hue C., Satchell S.C., Mathieson P.W., Mousson C., Noël C., Sautes-Fridman C., Halbwachs-Mecarelli L., Atkinson J.P., Lionet A., Frémeaux-Bacchi V., A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191.
29. Sharma A.P., Greenberg C.R., Prasad A.N., Prasad C., Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol, 2007, 22, 2097-2103.
30. Tarr P.I., Gordon C.A., Chandler W.L., Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet, 2005, 365, 1073-1086.
31. Trachtman H., Austin C., Lewinski M., Stahl R.A., Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol, 2012, 8, 658-669.
32. Walport M.J., Complement. First of two parts. N Engl J Med, 2001 a, 344, 1058-1066.
33. Walport M.J., Complement. Second of two parts. N Engl J Med, 2001 b, 344, 1140-1144.
34. Warwicker P., Goodship T.H., Donne R.L., Pirson Y., Nicholls A., Ward R.M., Turnpenny P., Goodship J.A., Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int, 1998, 53, 836-844.
35. Zoja C., Locatelli M., Pagani C., Corna D., Zanchi C., Isermann B., Remuzzi G., Conway E.M., Noris M., Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol, 2012, 189, 3661-3668.
36. Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Frémeaux-Bacchi V., Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol, 2012, 8, 643-657.